Please login to the form below

Not currently logged in
Email:
Password:

Boehringer Ingelheim collaboration

Boehringer Ingelheim and 4-Antibody are to collaborate on the development of fully human therapeutic antibodies for various disease indications

Boehringer Ingelheim and 4-Antibody are to collaborate on a long-term project to discover and develop fully human therapeutic antibodies for targets in various disease indications. 

Swiss-based 4-Antibody will use its proprietary and unencumbered Hu-PAC and Retrocyte Display technologies for the discovery and development of fully human antibodies against novel targets nominated by Boehringer Ingelheim. 4-Antibody will receive payments of up to €177.5m (CHF 266m) including upfront and milestone payments from Boehringer Ingelheim upon achievement of certain clinical development milestones. Further financial details were not disclosed. 

Dr Ulf Grawunder, co-founder and CSO of 4-Antibody, said: "This is a landmark agreement for 4-Antibody. We are delighted to commence a long-term collaboration with Boehringer Ingelheim and to apply the strength of 4-Antibody's fully human antibody discovery and engineering platforms to create valuable potential new drug candidates. Our unique and unencumbered technology capabilities allow the efficient generation of novel or improved fully human antibodies against any target class for our collaboration partners and for our own clinical development pipeline." 

4-Antibody owns four patent families related to therapeutic antibody discovery platforms and products, including more than a dozen granted patents worldwide. It has headquarters in Basel, with a subsidiary in Jena, Germany. 

17th March 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
IPG Health Medical Communications

We are the world's most celebrated and awarded Medical Communications agencies. We are 800 experts obsessed with combining science, creativity...

Latest intelligence

dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...
Mainimage2
The role of digital health technology tools in supporting medical adherence
How DHT-based digital interventions can help to support patients and improve adherence...